Regulating the stability and localization of CDK inhibitor p27^Kip1 via CSN6-COP1 axis

References

• Wei N, Deng XW. Making sense of the COP9 signalosome. A regulatory protein complex conserved from Arabidopsis to human. Trends Genet 1999; 15:98-103; PMID:10203806; http://dx.doi.org/10.1016/S0168-9525(98)01670-9
   PubMed Web of Science ®Google Scholar
• Seeger M, Kraft R, Ferrell K, Bech-Otschir D, Dumdey R, Schade R, Gordon C, Naumann M, Dubiel W. A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J 1998; 12:469-78; PMID:9535219
   PubMed Web of Science ®Google Scholar
• Zhang XC, Chen J, Su CH, Yang HY, Lee MH. Roles for CSN5 in control of p53/MDM2 activities. J Cell Biochem 2008; 103:1219-30; PMID:17879958; http://dx.doi.org/10.1002/jcb.21504
   PubMed Web of Science ®Google Scholar
• Chen B, Zhao R, Su CH, Linan M, Tseng C, Phan L, Fang L, Yang HY, Yang H, Wang W, et al. CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6. Cell Cycle 2012; 11:4633-41; PMID:23187808; http://dx.doi.org/10.4161/cc.22887
   PubMed Web of Science ®Google Scholar
• Xue Y, Chen J, Choi HH, Phan L, Chou PC, Zhao R, Yang H, Santiago J, Liu M, Yeung GE, et al. HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53. Cell Cycle 2012; 11:4181-90; PMID:23095642; http://dx.doi.org/10.4161/cc.22413
   PubMed Web of Science ®Google Scholar
• Choi HH, Gully C, Su CH, Velazquez-Torres G, Chou PC, Tseng C, Zhao R, Phan L, Shaiken T, Chen J, et al. COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3sigma. Oncogene 2011; 30:4791-801; PMID:21625211; http://dx.doi.org/10.1038/onc.2011.192
   PubMed Web of Science ®Google Scholar
• Choi HH, Su CH, Fang LK, Zhang J, Yeung SC, Lee MH. CSN6 deregulation impairs genome integrity in a COP1-dependent pathway. Oncotarget 2015; in press
   Web of Science ®Google Scholar
• Richardson KS, Zundel W. The emerging role of the COP9 signalosome in cancer. Mol Cancer Res 2005; 3:645-53; PMID:16380502; http://dx.doi.org/10.1158/1541-7786.MCR-05-0233
   PubMed Web of Science ®Google Scholar
• Zhao R, Phan L, Chen B, Yang HY, Chen J, Che TF, Qiao Y, Zhang J, Yeung SC, Lee MH. Ubiquitination-mediated p57Kip2 Degradation by CSN5 Confers Cancer Cell Proliferation. Cancer Hallmarks 2014; 1:133-44; http://dx.doi.org/10.1166/ch.2013.1013
   Google Scholar
• Zhao R, Yeung SC, Chen J, Iwakuma T, Su CH, Chen B, Qu C, Zhang F, Chen YT, Lin YL, et al. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest 2011; 121:851-65; PMID:21317535; http://dx.doi.org/10.1172/JCI44111
   PubMed Web of Science ®Google Scholar
• Chen J, Shin JH, Zhao R, Phan L, Wang H, Xue Y, Post SM, Ho Choi H, Chen JS, Wang E, et al. CSN6 drives carcinogenesis by positively regulating Myc stability. Nat Commun 2014; 5:5384; PMID:25395170; http://dx.doi.org/10.1038/ncomms6384
   PubMed Web of Science ®Google Scholar
• Lee MH, Zhao R, Phan L, Yeung SC. Roles of COP9 signalosome in cancer. Cell Cycle 2011; 10:3057-66; PMID:21876386; http://dx.doi.org/10.4161/cc.10.18.17320
   PubMed Web of Science ®Google Scholar
• Salmena L, Hakem R. From photomorphogenesis to cancer: a CSN journey. Cell Cycle 2013; 12:205-6; PMID:23287466; http://dx.doi.org/10.4161/cc.23422
   PubMed Web of Science ®Google Scholar
• Wei W, Kaelin WG, Jr. Good COP1 or bad COP1? In vivo veritas. J Clin Invest 2011; 121:1263-5; PMID:21403396; http://dx.doi.org/10.1172/JCI57080
   PubMed Web of Science ®Google Scholar
• Marine JC. Spotlight on the role of COP1 in tumorigenesis. Nature reviews Cancer 2012; 12:455-64; PMID:22673153; http://dx.doi.org/10.1038/nrc3271
   PubMed Web of Science ®Google Scholar
• Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78:59-66; PMID:8033212; http://dx.doi.org/10.1016/0092-8674(94)90572-X
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Demidenko ZN, Blagosklonny MV. Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program. Proc Natl Acad Sci U S A 2014; 111:8832-7.
   Google Scholar
• Yang HY, Zhou BP, Hung MC, Lee MH. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 2000; 275:24735-9; PMID:10859299; http://dx.doi.org/10.1074/jbc.C000147200
   PubMed Web of Science ®Google Scholar
• Newman L, Xia W, Yang HY, Sahin A, Bondy M, Lukmanji F, Hung MC, Lee MH. Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog 2001; 30:169-75; PMID:11301477; http://dx.doi.org/10.1002/mc.1025
   PubMed Web of Science ®Google Scholar
• Yang HY, Shao R, Hung MC, Lee MH. p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis. Oncogene 2001; 20:3695-702; PMID:11439332; http://dx.doi.org/10.1038/sj.onc.1204472
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang HY, Zhang XC, Yang H, Tsai M, Lee MH. Tumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growth. Oncogene 2004; 23:7132-43; PMID:15273726; http://dx.doi.org/10.1038/sj.onc.1207918
   PubMed Web of Science ®Google Scholar
• Yang H, Zhao R, Yang HY, Lee MH. Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity. Oncogene 2005; 24:1924-35; PMID:15688030; http://dx.doi.org/10.1038/sj.onc.1208352
   PubMed Web of Science ®Google Scholar
• Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8:1153-60. Epub 2002 Sep 16; PMID:12244302; http://dx.doi.org/10.1038/nm761
   PubMed Web of Science ®Google Scholar
• Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001; 58:1907-22; PMID:11766887; http://dx.doi.org/10.1007/PL00000826
   PubMed Web of Science ®Google Scholar
• Caraballo JM, Acosta JC, Cortes MA, Albajar M, Gomez-Casares MT, Batlle-Lopez A, Cuadrado MA, Onaindia A, Bretones G, Llorca J, et al. High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle. Oncotarget 2014; 5:4694-708; PMID:25051361
   PubMed Web of Science ®Google Scholar
• Zhao H, Faltermeier CM, Mendelsohn L, Porter PL, Clurman BE, Roberts JM. Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy. Oncotarget 2014; 5:12704-14; PMID:25587029
   PubMed Web of Science ®Google Scholar
• Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372:570-3; PMID:7990932; http://dx.doi.org/10.1038/372570a0
   PubMed Web of Science ®Google Scholar
• Yang H, Zhang Y, Zhao R, Wen YY, Fournier K, Wu HB, Yang HY, Diaz J, Laronga C, Lee MH. Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt. Oncogene 2006; 25:4585-94; PMID:16532026; http://dx.doi.org/10.1038/sj.onc.1209481
   PubMed Web of Science ®Google Scholar
• Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1:193-9; PMID:10559916; http://dx.doi.org/10.1038/12013
   PubMed Web of Science ®Google Scholar
• Choi HH, Fang LK, Chen JS, Chou PC, Phan L, Su CH, Ivan C, Baggery K, Sood A, Yeung SC, et al. COP1 enhances ubiquitin-mediated degradation of p27Kip1 to promote cancer cell growth. Oncotarget 2015; in press
   Web of Science ®Google Scholar
• Pippa R, Espinosa L, Gundem G, Garcia-Escudero R, Dominguez A, Orlando S, Gallastegui E, Saiz C, Besson A, Pujol MJ, et al. p27Kip1 represses transcription by direct interaction with p130/E2F4 at the promoters of target genes. Oncogene 2012; 31:4207-20; PMID:22179826; http://dx.doi.org/10.1038/onc.2011.582
   PubMed Web of Science ®Google Scholar
• Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H, Dixit VM. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004; 429:86-92. Epub 2004 Apr 21; PMID:15103385; http://dx.doi.org/10.1038/nature02514
   PubMed Web of Science ®Google Scholar
• Migliorini D, Bogaerts S, Defever D, Vyas R, Denecker G, Radaelli E, Zwolinska A, Depaepe V, Hochepied T, Skarnes WC, et al. Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J Clin Invest 2011; 121:1329-43; PMID:21403399; http://dx.doi.org/10.1172/JCI45784
   PubMed Web of Science ®Google Scholar
• Vitari AC, Leong KG, Newton K, Yee C, O'Rourke K, Liu J, Phu L, Vij R, Ferrando R, Couto SS, et al. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature 2011; 474:403-6; PMID:21572435; http://dx.doi.org/10.1038/nature10005
   PubMed Web of Science ®Google Scholar
• Dornan D, Shimizu H, Mah A, Dudhela T, Eby M, O'Rourke K, Seshagiri S, Dixit VM. ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Science 2006; 313:1122-6; PMID:16931761; http://dx.doi.org/10.1126/science.1127335
   PubMed Web of Science ®Google Scholar
• Su CH, Zhao R, Velazquez-Torres G, Chen J, Gully C, Yeung SC, Lee MH. Nuclear export regulation of COP1 by 14-3-3sigma in response to DNA damage. Mol Cancer 2010; 9:243; PMID:20843328; http://dx.doi.org/10.1186/1476-4598-9-243
   PubMed Web of Science ®Google Scholar
• Su CH, Zhao R, Zhang F, Qu C, Chen B, Feng YH, Phan L, Chen J, Wang H, Yeung SC, et al. 14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability. Cancer Res 2011; 71:884-94; PMID:21135113; http://dx.doi.org/10.1158/0008-5472.CAN-10-2518
   PubMed Web of Science ®Google Scholar
• Wu FY, Wang SE, Sanders ME, Shin I, Rojo F, Baselga J, Arteaga CL. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res 2006; 66:2162-72; PMID:16489017; http://dx.doi.org/10.1158/0008-5472.CAN-05-3304
   PubMed Web of Science ®Google Scholar
• Wu CC, Yang TY, Yu CT, Phan L, Ivan C, Sood AK, Hsu SL, Lee MH. p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. Cell Cycle 2012; 11:3433-42; PMID:22894933; http://dx.doi.org/10.4161/cc.21732
   PubMed Web of Science ®Google Scholar
• Fang L, Yang Z, Zhou J, Yeung SC, Tung JY, Hsiao CD, Wang L, Deng Y, Wang P, Wang J, et al. Circadian clock gene CRY2 degradation is involved in chemoresistance of colorectal cancer. Molecular Cancer Therapeutics 2015; in press; PMID:25855785
   PubMed Web of Science ®Google Scholar
• Laronga C, Yang HY, Neal C, Lee MH. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 2000; 275:23106-12; PMID:10767298; http://dx.doi.org/10.1074/jbc.M905616199
   PubMed Web of Science ®Google Scholar
• Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, Chen J, et al. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. J Natl Cancer Inst 2014; 106; PMID:24957076; http://dx.doi.org/10.1093/jnci/dju158
   PubMed Web of Science ®Google Scholar
• Wen YY, Chou PC, Pham L, Su CH, Chen J, Hsieh YC, Xue Y-W, Qu C-J, Gully C, Parreno K, et al. DNA damage-mediated c-Myc degradation requires 14-3-3 sigma. Cancer Hallmarks 2013; 1:3-17; http://dx.doi.org/10.1166/ch.2013.1002
   Google Scholar
• Gully CP, Velazquez-Torres G, Shin JH, Fuentes-Mattei E, Wang E, Carlock C, Chen J, Rothenberg D, Adams HP, Choi HH, et al. Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci U S A 2012; 109:E1513-22; PMID:22611192; http://dx.doi.org/10.1073/pnas.1110287109
   PubMed Web of Science ®Google Scholar
• Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, Yeung SC, Lee MH. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer 2010; 9:42; PMID:20175926; http://dx.doi.org/10.1186/1476-4598-9-42
   PubMed Web of Science ®Google Scholar
• Phan L, Shin JH, Zhou Z, Gully C, Phan L, Velazquez-Torres T, Fuentes-Mattei E, Yeung G, Su CH, Wang H, et al. The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming Nat Commun 2015; in press
   Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, et al. The molecular classification of multiple myeloma. Blood 2006; 108:2020-8; PMID:16728703; http://dx.doi.org/10.1182/blood-2005-11-013458
   PubMed Web of Science ®Google Scholar